Journal
JOURNAL OF NEUROIMMUNOLOGY
Volume 157, Issue 1-2, Pages 197-202Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jneuroim.2004.08.029
Keywords
HIV-associated dementia; apolipoprotein; aging
Categories
Funding
- NCRR NIH HHS [G12RR/AI 03061, G12 RR003061-20, P20 RR11091, U54 RR014607-05, P20 RR011091-11] Funding Source: Medline
- NINDS NIH HHS [1U54NS43049, U54 NS043049-05] Funding Source: Medline
Ask authors/readers for more resources
There are discrepant findings regarding the risk of HIV-associated dementia (HAD) relating to apolipoprotein E4, suggesting other factors may modulate risk. Furthermore, evidence suggests a changing phenotype of HAD in the era of highly active antiretroviral therapy (HAART), prompting a need to determine if new disease markers have emerged. In this analysis, APOE genotype was determined for 182 participants enrolled in the Hawaii Aging with HIV Cohort. After controlling for age and diabetes status, an independent risk of HAD relating to E4 was seen in older participants [OR=2.898 (1.031-8.244)] but not in younger participants [OR=0.373 (0.054-1.581)]. Several proposed mechanisms may underlie this association. Consideration of non-traditional risk factors for HAD in older HIV patients may yield new markers of disease in the era of HAART. (C) 2004 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available